Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVX-03
- Development stage
- Discontinued
- Lead developer
- Evaxion Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
EVX-03 is a DNA-based personalized neoantigen cancer vaccine developed by Evaxion Biotech. It is designed as an immunotherapy for the treatment of advanced solid tumors, with a primary focus on non-small cell lung cancer (NSCLC). The vaccine utilizes Evaxion’s AI-driven platform to identify patient-specific tumor neoantigens and endogenous retrovirus (ERV) fragments. These are encoded into a plasmid construct that also includes a genetic immune adjuvant and an antigen-presenting cell (APC)-targeting unit to enhance immune response. Preclinical studies have shown significant tumor reduction at low doses and robust immunogenicity. As of late 2024, EVX-03 remains in preclinical development with plans for clinical trials targeting NSCLC[1][4][5][6][8].
- Other names
- EVX-03EVX03EVX 03
Beyond the preview
Go deeper on EVX-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVX-03.